European Journal of Clinical Pharmacology

, Volume 34, Issue 3, pp 307–308 | Cite as

Acetylator polymorphism in discoid lupus erythematosus

  • J. M. Ladero
  • L. C. Jiménez
  • M. J. Fernández
  • A. Robledo
Short Communications

Summary

Acetylator phenotype was determined, using sulphamethazine, in 37 patients with histologically confirmed discoid lupus erythematosus, who were free from visceral damage, and in 157 normal control subjects. Twenty patients (54%) and 90 control subjects (57.4%) were slow acetylators (p not significant). Acetylator polymorphism appears not to be related to the risk of developing pure cutaneous discoid lupus erythematosus.

Key words

acetylator phenotype lupus erythematosus sulphamethazine 

References

  1. 1.
    Weber WW, Hein DW (1985) N-Acetylation pharmacogenetics. Pharmacol Rev 37: 25–79Google Scholar
  2. 2.
    Reidenberg MM, Levy M, Drayer DE, Zylber-Katz E, Robbins WC (1980) Acetylator phenotype in idiopatic systemic lupus erythematosus. Arthritis Rheum 23: 569–573Google Scholar
  3. 3.
    Clark DWJ (1985) Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs 29: 342–375Google Scholar
  4. 4.
    Evans DAP (1984) Survey of the human acetylator polymorphism in spontaneous disorders. J Med Genet 21: 243–253Google Scholar
  5. 5.
    Bauer R, Orfanos CE (1983) Contemporary aspects of lupus erythematosus and its subsets. In: Rook AJ, Maiboch HI (eds) Recent advances in dermatology. Churchill Livingstone, New YorkGoogle Scholar
  6. 6.
    Evans DAP, White TA (1964) Human acetylation polymorphism. J Lab Clin Med 63: 394–403Google Scholar
  7. 7.
    Evans DAP (1969) An improved and simplified method of detecting the acetylator phenotype. J Med Genet 6: 405–407Google Scholar
  8. 8.
    Ladero JM, Kwok CK, Jara C, Fernández L, Silmi AM, Tapia D, Uson AC (1985) Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 17: 96–99Google Scholar
  9. 9.
    Ladero JM, Arrojo A, Gilsanz V (1979) Acetilación hepática en la población española. Gastroenterol Hepatol 2: 236–240Google Scholar
  10. 10.
    Reidenberg MM, Martin JH (1974) Acetylator phenotype of patients with systemic lupus erythematosus. Drug Metab Dispos 2: 71–73Google Scholar
  11. 11.
    Larsson R, Karlsson E, Molin E (1977) Spontaneous systemic lupus erythematosus and acetylator phenotype. Acta Med Scand 201: 223–226Google Scholar
  12. 12.
    Lawson DH, Henry DA, Lowe J, Reavey P, Rennie JAN, Solomon A (1979) Acetylator phenotype in spontaneous SLE and rheumatoid arthritis. Ann Rheum Dis 38: 171–173Google Scholar
  13. 13.
    Fishbein E, Alarcón-Segovia D (1979) Slow acetylation phenotype in systemic lupus erythematosus. Arthritis Rheum 22: 95–96Google Scholar
  14. 14.
    Johansson EA, Mustakallio KK, Mattila MM, Tiilkainen A (1976) Cutaneous reactions to drugs, acetylation phenotype and HLA antigens in patients with and without systemic lupus erythematosus (SLE). Ann Clin Res 8: 126–128Google Scholar
  15. 15.
    Foad B, Litwin A, Zimmer H, Hess EV (1977) Acetylator phenotype in systemic lupus erythematosus. Arthritis Rheum 20: 815–818Google Scholar
  16. 16.
    Marsden JR, Mason GGF, Coburn PR, Rawlins MD, Shuster S (1985) Drug acetylation and expression of lupus erythematosus. Eur J Clin Pharmacol 28: 387–390Google Scholar
  17. 17.
    Vansant J, Woosley RL, John JT, Sergent JS (1978) Normal distribution of acetylator phenotypes in systemic lupus erythematosus. Arthritis Rheum 21: 192–195Google Scholar
  18. 18.
    Morris RJ, Freed CR, Kohler PF (1979) Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus. Arthritis Rheum 22: 777–780Google Scholar
  19. 19.
    Ehrlich GE, Freeman-Narrod M, Wineburg GS (1979) Predominance of slow acetylators among patients with rheumatoid arthritis. Eur J Rheumatol Inflam 2: 196–198Google Scholar
  20. 20.
    Ishizaki T, Horai J, Koya G, Matsuyama K, Iguchi S (1981) Acetylator phenotype and metabolic disposition of isoniazid in japanese patients with systemic lupus erythematosus. Arthritis Rheum 24: 1245–1254Google Scholar
  21. 21.
    Sardas S, Karakaya AE, Sardas OS (1986) Acetylator phenotype in patients with hepatic systemic lupus erythematosus. Arthritis Rheum 29: 1412–1413Google Scholar
  22. 22.
    Baer AN, Woosley RL, Pincus T (1986) Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. Arthritis Rheum 29: 508–514Google Scholar
  23. 23.
    Paulsen O, Nilsson LG (1985) Distribution of acetylator phenotype in relation to age and sex in swedish patients. Eur J Clin Pharmacol 28: 311–315Google Scholar
  24. 24.
    Tiitinen H (1969) Isoniazid and ethionamide serum levels and inactivation in finnish subjects. Scand J Respir Dis 50: 110–124Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • J. M. Ladero
    • 1
  • L. C. Jiménez
    • 1
  • M. J. Fernández
    • 1
  • A. Robledo
    • 1
  1. 1.Departments of Medicine and Medicine II (Dermatology)Hospital Universitario “San Carlos”, Facultad de Medicina, Universidad ComplutenseMadridSpain

Personalised recommendations